Scarica l'app Stockscreener
4.51
4.16%
0.18
Dopo l'orario di chiusura:
4.56
0.05
+1.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Galectin Therapeutics Inc Borsa (GALT) Ultime notizie
Form 4 Galectin Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock By Investing.com - Investing.com Australia
Galectin Therapeutics director sells $150,890 in common stock By Investing.com - Investing.com Canada
[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity - Stock Titan
Galectin Therapeutics (GALT) CMO exits 52,037 shares in pre-planned sale - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Top 3 Health Care Stocks That May Keep You Up At Night In June - Benzinga
Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Harold Shlevin files Form 144: GALT (NASDAQ) sale of 7,732 shares - Stock Titan
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2500 Growth Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2000 Index - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2000 Value Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Index - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Growth Benchmark - marketscreener.com
GALT jumps 11% on FDA alignment for belapectin phase III path in MASH - MSN
GALT stock surges 22% — on track for best day in over a year after FDA clears path for late-stage belapectin trial - MSN
Form 144 GALECTIN THERAPEUTICS INC For: 26 June - Investing.com UK
Galectin Therapeutics Inc (GALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 144 GALECTIN THERAPEUTICS INC For: 26 June By Investing.com - Investing.com Nigeria
GALT (NASDAQ: GALT) Rule 144 notice: Khurram Jamil reports share disposals - Stock Titan
Form 144 GALECTIN THERAPEUTICS INCORPORATED For: 26 June By Investing.com - Investing.com Canada
[144] GALECTIN THERAPEUTICS INC SEC Filing - Stock Titan
GALTGalectin Therapeutics Inc Revenue Breakdown - Finviz
$Galectin Therapeutics (GALT.US)$ The FIB Strikes Again!! - Moomoo
Galectin Therapeutics Inc. Actuals & Estimates (FWB:PHPN) - TradingView
GALT Forecast — Price Target — Prediction for 2027 - TradingView
Galectin Therapeutics CMO Jamil Khurram sells $23,728 in shares By Investing.com - Investing.com South Africa
Galectin Therapeutics CMO Jamil Khurram sells $23,728 in shares - Investing.com
Form 4 Galectin Therapeutics Inc For: 25 June By Investing.com - Investing.com South Africa
Galectin (NASDAQ: GALT) CMO exercises options and sells 7,557 shares under 10b5-1 plan - Stock Titan
PHPN Forecast — Price Target — Prediction for 2027 - TradingView
Galectin Therapeutics(GALT) Stock Options Chain | Quotes & News - Moomoo
Galectin Therapeutics (GALT) Short Interest & Short Float | Updated Jun 2026 $GALT - MarketBeat
FDA alignment reduces risk for Galectin Therapeutics' belapectin Phase 3 trial, keeping it a buy. - Pluang
Galectin De-Risks Belapectin Path With FDA AlignmentSets Stage For Phase 3 Upside - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) and Gilead Sciences (GILD) - The Globe and Mail
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH - The Globe and Mail
H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Form 144 GALECTIN THERAPEUTICS INC For: 23 June By Investing.com - Investing.com Australia
Form 144 GALECTIN THERAPEUTICS INC For: 23 June - Investing.com UK
GALT affiliate notifies sale of 8,125 shares (NASDAQ: GALT) - Stock Titan
Galectin Therapeutics (GALT) Announces FDA Agreement for Phase 3 Program - GuruFocus
GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial - Asianet Newsable
Galectin reaches FDA agreement on Phase 3 trial for belapectin By Investing.com - Investing.com South Africa
Galectin Therapeutics stock surges on FDA trial agreement - Investing.com
Galectin Therapeutics stock surges on FDA trial agreement By Investing.com - Investing.com South Africa
3.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):